Cargando…

Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324...

Descripción completa

Detalles Bibliográficos
Autores principales: Sindi, Hebah A., Russomanno, Giusy, Satta, Sandro, Abdul-Salam, Vahitha B., Jo, Kyeong Beom, Qazi-Chaudhry, Basma, Ainscough, Alexander J., Szulcek, Robert, Jan Bogaard, Harm, Morgan, Claire C., Pullamsetti, Soni S., Alzaydi, Mai M., Rhodes, Christopher J., Piva, Roberto, Eichstaedt, Christina A., Grünig, Ekkehard, Wilkins, Martin R., Wojciak-Stothard, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055281/
https://www.ncbi.nlm.nih.gov/pubmed/32132543
http://dx.doi.org/10.1038/s41467-020-14966-x
Descripción
Sumario:Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.